Your browser doesn't support javascript.
loading
Drug-coated balloons in below-the-knee arteries.
Stoll, Felicitas; Uslu, Reyhan; Blessing, Erwin; Frey, Norbert; Katus, Hugo A; Erbel, Christian; Heilmeier, Britta; Müller, Oliver J.
Afiliação
  • Stoll F; Department of Cardiology, Angiology, Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
  • Uslu R; Department of Cardiology, Angiology, Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
  • Blessing E; SRH Klinikum Karlsbad-Langensteinbach, Karlsbad, Germany.
  • Frey N; Department of Cardiology, Angiology, Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
  • Katus HA; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Germany.
  • Erbel C; Department of Cardiology, Angiology, Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
  • Heilmeier B; German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Germany.
  • Müller OJ; Department of Cardiology, Angiology, Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
Vasa ; 51(4): 256-262, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35604329
ABSTRACT

Background:

The search for an optimal interventional treatment strategy in infrapopliteal peripheral artery disease remains in the focus of interest. Whether drug-coated balloons (DCB) might enhance interventional outcomes after crural interventions is a matter of debate, as studies yielded conflicting results on DCB safety and efficacy. Patients and

methods:

We analyzed a retrospective cohort of 75 infrapopliteal DCB interventions performed at our institution in 68 patients with peripheral artery disease in Rutherford category 3 to 6.

Results:

Despite a high rate of long complex lesions and multi-vessel disease, freedom from clinically driven target lesions revascularization (TLR) after 365 days was 68%. After six months, healing or significant improvement of the ischemic ulcer was observed in 78% of cases. Accordingly, freedom from major amputation and death after 365 days was 82%. Freedom from major amputation and death was 76.2% of cases in patients with diabetes mellitus as opposed to 91.5% in patients without diabetes mellitus (p=0.049).

Conclusions:

With this real-world analysis we would like to contribute to the ongoing discussion on the benefit and safety of DCB treatment in below-the-knee interventions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Angioplastia com Balão / Diabetes Mellitus / Doença Arterial Periférica Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Vasa Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Angioplastia com Balão / Diabetes Mellitus / Doença Arterial Periférica Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Vasa Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha